{
  "iteration": 14,
  "question_id": "index_13",
  "results_by_threshold": {
    "0.1": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.2": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.3": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.4": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.5": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.6": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.7": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.75": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.8": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 9,
          "thought2_idx": 2,
          "text1": "Alternatively, maybe the regions where peaks disappear are places where the antibody can't access IKAROS when crosslinked with DSG. For example, if IKAROS is part of a large complex, maybe the epitope (the part the antibody binds to) is masked by the crosslinks. But that's a bit uncertain. \n\nThe options are A) repeats, B) introns of large genes, C) random, D) active promoters/enhancers. \n\nThe key here might be that active promoters and enhancers have more protein complexes. So when you use DSG, which crosslinks proteins to proteins, those regions where IKAROS is part of a complex (like at active sites) would be better preserved, but maybe the peaks that disappear are in regions that are not part of such complexes.",
          "text2": "Alternatively, maybe the presence of DSG creates more stable protein-protein interactions. If the IKAROS is part of a larger complex, maybe the antibody can't bind as effectively when there's more crosslinking. Or maybe the peaks that disappeared are regions where IKAROS is only weakly bound, and the additional crosslinking stabilizes only the strong interactions, but that might not explain the disappearance.",
          "score": 0.8884751796722412
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    },
    "0.9": {
      "detected_pairs": [
        {
          "chain1_id": "q14_c2",
          "chain2_id": "q14_c1",
          "thought1_idx": 12,
          "thought2_idx": 7,
          "text1": "Wait, maybe the peaks that disappear are regions where the IKAROS is only transiently bound, and in PFA+DSG, which has better crosslinking (because of both DNA and protein crosslinks), those regions aren't captured because the crosslinking is more thorough. Or maybe the other way around.",
          "text2": "Alternatively, maybe the peaks that disappear are regions where IKAROS is only transiently associated, so with stronger crosslinking (PFA+DSG), only the tightly bound regions remain, but those that were present with just PFA (weaker crosslinking) are lost.",
          "score": 0.9029486179351807
        }
      ],
      "num_detected": 1,
      "num_same_answer": 0,
      "same_answer_perc": 0.0
    }
  }
}